Difficulty: Medium
Average Score: 92%
Practice
A patient with end-stage renal failure has been admitted to the hospital for severe anemia. She is refusing blood transfusions. The nurse anticipates drug therapy with which drug to stimulate the production of red blood cells?
Correct answer
C
Rationale
In this scenario, the correct answer is C) epoetin alfa (Epogen). Epoetin alfa is a recombinant form of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production in the bone marrow. In end-stage renal failure, the kidneys are unable to produce enough erythropoietin, leading to anemia. By administering epoetin alfa, we can help stimulate the production of red blood cells and improve the patient's anemia without the need for a blood transfusion.
Now, let's analyze why the other options are incorrect:
A) Folic acid is essential for DNA synthesis and red blood cell production, but it does not directly stimulate red blood cell production in the same way as erythropoietin.
B) Cyanocobalamin (vitamin B12) is important for red blood cell production and neurological function, particularly in cases of B12 deficiency anemia. However, it does not directly stimulate red blood cell production in the context of end-stage renal failure.
D) Filgrastim (Neupogen) is a granulocyte colony-stimulating factor used to stimulate the production of white blood cells, not red blood cells. It is not indicated for treating anemia in end-stage renal failure.
In an educational context, understanding the mechanisms of action of different drugs is crucial for healthcare professionals to make informed decisions in patient care. Knowing the specific indications and contraindications of medications allows for safe and effective treatment strategies to be implemented.
Now, let's analyze why the other options are incorrect:
A) Folic acid is essential for DNA synthesis and red blood cell production, but it does not directly stimulate red blood cell production in the same way as erythropoietin.
B) Cyanocobalamin (vitamin B12) is important for red blood cell production and neurological function, particularly in cases of B12 deficiency anemia. However, it does not directly stimulate red blood cell production in the context of end-stage renal failure.
D) Filgrastim (Neupogen) is a granulocyte colony-stimulating factor used to stimulate the production of white blood cells, not red blood cells. It is not indicated for treating anemia in end-stage renal failure.
In an educational context, understanding the mechanisms of action of different drugs is crucial for healthcare professionals to make informed decisions in patient care. Knowing the specific indications and contraindications of medications allows for safe and effective treatment strategies to be implemented.